Citigroup Inc Cure Vac N.V. Transaction History

Citigroup Inc

$169 Billion
Q3 2024

A detailed history of Citigroup Inc transactions in Cure Vac N.V. stock. As of the latest transaction made, Citigroup Inc holds 8,299 shares of CVAC stock, worth $25,311. This represents 0.0% of its overall portfolio holdings.

Number of Shares

8,299

Previous 9,615 13.69%

Holding current value

$25,311

Previous $32,000 25.0%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 12, 2024	SELL	$2.74 - $3.79 $3,605 - $4,987	-1,316 Reduced 13.69%	8,299 $24,000
Q2 2024 Aug 12, 2024	BUY	$2.31 - $4.99 $8,757 - $18,917	3,791 Added 65.09%	9,615 $32,000
Q1 2024 May 10, 2024	SELL	$2.94 - $4.34 $11,101 - $16,387	-3,776 Reduced 39.33%	5,824 $17,000
Q4 2023 Feb 09, 2024	SELL	$3.96 - $6.41 $1,884 - $3,051	-476 Reduced 4.72%	9,600 $40,000
Q3 2023 Nov 09, 2023	SELL	$6.5 - $10.77 $22,197 - $36,779	-3,415 Reduced 25.31%	10,076 $68,000
Q2 2023 Aug 10, 2023	BUY	$6.69 - $12.25 $8,382 - $15,349	1,253 Added 10.24%	13,491 $140,000
Q1 2023 May 11, 2023	SELL	$6.38 - $12.5 $9,499 - $18,612	-1,489 Reduced 10.85%	12,238 $85,000
Q4 2022 Feb 09, 2023	BUY	$5.75 - $8.5 $31,860 - $47,098	5,541 Added 67.69%	13,727 $82,000
Q3 2022 Nov 10, 2022	SELL	$7.48 - $15.24 $7,135 - $14,538	-954 Reduced 10.44%	8,186 $64,000
Q2 2022 Aug 10, 2022	SELL	$13.18 - $19.41 $96,596 - $142,255	-7,329 Reduced 44.5%	9,140 $124,000
Q1 2022 May 12, 2022	SELL	$14.73 - $35.25 $321,452 - $769,260	-21,823 Reduced 56.99%	16,469 $323,000
Q4 2021 Feb 10, 2022	SELL	$33.72 - $48.22 $3.22 Million - $4.6 Million	-95,446 Reduced 71.37%	38,292 $1.31 Million
Q3 2021 Nov 10, 2021	BUY	$49.26 - $74.5 $6.59 Million - $9.96 Million	133,738 New	133,738 $7.31 Million

Others Institutions Holding CVAC

# of Institutions

Shares Held

12.3M

Call Options Held

164K

Put Options Held

117K

View Full List

About CureVac N.V.

Ticker CVAC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 187,467,008
Market Cap $572M
Description
CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202, a prophylactic mRNA-based vaccine, which ...

More about CVAC

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

News

Stay updated on Citigroup Inc with notifications on news.

Account